tiprankstipranks
Advertisement
Advertisement

AMLX Stock Latest News

Amylyx announces launch of U.S. EAP for adults with PBH
The FlyAmylyx announces launch of U.S. EAP for adults with PBH
2d ago
AMLX
Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch
PremiumCompany Announcements
Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch
7d ago
AMLX
Amylyx price target raised to $21 from $19 at Mizuho
PremiumThe Fly
Amylyx price target raised to $21 from $19 at Mizuho
9d ago
AMLX
Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential
PremiumRatings
Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential
29d ago
AMLX
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation
PremiumCompany Announcements
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation
1M ago
8K
AMLX
Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide
PremiumThe FlyAmylyx completes enrollment in Phase 3 Lucidity trial of avexitide
1M ago
AMLX
Amylyx price target raised to $30 from $25 at Guggenheim
Premium
The Fly
Amylyx price target raised to $30 from $25 at Guggenheim
2M ago
AMLX
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program
Premium
Ratings
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program
2M ago
AMLX
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027
PremiumCompany Announcements
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027
2M ago
AMLX
Amylyx price target raised to $34 from $28 at H.C. Wainwright
PremiumThe Fly
Amylyx price target raised to $34 from $28 at H.C. Wainwright
2M ago
AMLX
Amylyx Pharmaceuticals: Solid Balance Sheet, Advancing Pipeline, and Attractive Risk‑Reward Support Buy Rating
PremiumRatings
Amylyx Pharmaceuticals: Solid Balance Sheet, Advancing Pipeline, and Attractive Risk‑Reward Support Buy Rating
2M ago
AMLX
Amylyx files automatic mixed securities shelf
PremiumThe Fly
Amylyx files automatic mixed securities shelf
2M ago
AMLX
Amylyx reports Q4 EPS (30c), consensus (34c)
PremiumThe FlyAmylyx reports Q4 EPS (30c), consensus (34c)
2M ago
AMLX
Amylyx initiated with a Buy at Stifel
Premium
The Fly
Amylyx initiated with a Buy at Stifel
2M ago
AMLX
Is AMLX a Buy, Before Earnings?
Premium
Pre-Earnings
Is AMLX a Buy, Before Earnings?
2M ago
AMLX
Amylyx price target raised to $19 from $15 at BofA
PremiumThe Fly
Amylyx price target raised to $19 from $15 at BofA
3M ago
AMLX
Amylyx price target raised to $19 from $18 at Mizuho
PremiumThe Fly
Amylyx price target raised to $19 from $18 at Mizuho
3M ago
AMLX
Amylyx price target raised to $19 from $18 at Mizuho
PremiumThe Fly
Amylyx price target raised to $19 from $18 at Mizuho
3M ago
AMLX
Amylyx price target raised to $28 from $20 at H.C. Wainwright
PremiumThe Fly
Amylyx price target raised to $28 from $20 at H.C. Wainwright
3M ago
AMLX
Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside
PremiumRatingsBuy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside
4M ago
AMLX
Amylyx Advances AMX0318 as New Rare-Disease Candidate
Premium
Company Announcements
Amylyx Advances AMX0318 as New Rare-Disease Candidate
4M ago
8K
AMLX
Amylyx selects AMX0318 as development candidate for PBH
Premium
The Fly
Amylyx selects AMX0318 as development candidate for PBH
4M ago
AMLX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >